Verus Capital Partners’s Boston Scientific BSX Stock Holding History

Verus Capital Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,493	Closed	-$238K	–	473
2025 Q4	$238K	Sell	2,493 -55	-2%	-$5.39K	0.02%	395
2025 Q3	$249K	Buy	2,548 +493	+24%	+$51.1K	0.02%	357
2025 Q2	$221K	Buy	2,055 +5	+0.2%	+$506	0.02%	336
2025 Q1	$207K	Buy	+2,050	New	+$206K	0.02%	349
2020 Q1	$331K	Sell	10,150 -2,750	-21%	-$107K	0.1%	126
2019 Q4	$583K	Buy	+12,900	New	+$540K	0.19%	87

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verus Capital Partners's BSX Position: Q1 2026 in Review

Verus Capital Partners sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,493 shares — an estimated $238K sold.

Verus Capital Partners first reported a position in BSX in Q4 2019 and held it in 6 quarters. The position peaked at $583K in Q4 2019. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Verus Capital Partners reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Verus Capital Partners sold 2,493 Boston Scientific shares in Q1 2026, an estimated $238K.
Verus Capital Partners first reported a position in Boston Scientific in Q4 2019 and held it in 6 quarters.
Verus Capital Partners's Boston Scientific position peaked at $583K in Q4 2019.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.